➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
Express Scripts
McKesson
McKinsey
Boehringer Ingelheim

Last Updated: September 24, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR GALLIUM DOTATOC GA 68

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for GALLIUM DOTATOC GA 68

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01619865 Safety and Efficacy of 68Ga-DOTA-tyr3-Octreotide Active, not recruiting University of Iowa N/A 2012-02-01 This protocol is designed to test the efficacy of 68Ga-DOTATOC PET/CT in diagnosis, staging, and measurement of response to treatment in patients with somatostatin receptor positive tumors. We will 1) compare this unique PET/CT scan with the current standard of care which is a combination of Octreoscan SPECT (single photon emission tomography) plus a high resolution, contrast enhanced CT; 2) Determine the sensitivity of 68Ga-DOTATOC PET/CT in diagnosis of patients with suspected somatostatin receptor positive tumor; and 3) For those patients who have had recent treatment (e.g., surgery, chemotherapy, targeted therapy such as anti-angiogenics, kinase inhibitors, peptide receptor radiotherapy), we will measure response to treatment. These studies will be obtained with the long term goal of submitting a New Drug Application (NDA) for FDA approval of 68Ga-DOTATOC PET/CT in adults and children.
NCT02375464 Gallium-68 DOTATOC for Management of Neuroendocrine Tumors No longer available Northwell Health Phase 3 2015-04-01 Gallium-68 DOTATOC is a material used to find neuroendocrine tumors (NETs) using positron emission tomography (PET scan). The material has already been shown to be better than the currently available imaging agents. This study is designed to evaluate the clinical impact of PET CT scanning using this agent in the evaluation and management of patients with NETs.
NCT03001349 68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors Active, not recruiting National Cancer Institute (NCI) Early Phase 1 2017-05-16 This trial studies how well gallium Ga 68-edotreotide (68Ga-DOTA-TOC) positron emission tomography (PET)/computer tomography (CT) works in imaging participants with neuroendocrine tumors. 68Ga-DOTA-TOC is used as a tracer chemical during PET/CT scans. Diagnostic procedures, such as 68Ga-DOTA-TOC PET/CT, may help find and diagnose neuroendocrine tumors.
NCT03001349 68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors Active, not recruiting M.D. Anderson Cancer Center Early Phase 1 2017-05-16 This trial studies how well gallium Ga 68-edotreotide (68Ga-DOTA-TOC) positron emission tomography (PET)/computer tomography (CT) works in imaging participants with neuroendocrine tumors. 68Ga-DOTA-TOC is used as a tracer chemical during PET/CT scans. Diagnostic procedures, such as 68Ga-DOTA-TOC PET/CT, may help find and diagnose neuroendocrine tumors.
NCT03136328 Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET/CT Scan Completed NCM USA Phase 3 2016-05-16 The primary goal of the analysis is to estimate the diagnostic accuracy of Gallium 68 (68Ga) -DOTATOC PET/CT for detecting neuroendocrine tumors (NETs) compared to conventional imaging techniques such as Magnetic Resonance Imaging (MRI) and Computerized Tomography (CT). Participants with histologically and/or clinically confirmed and/or suspected NET will be enrolled.
NCT03136328 Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET/CT Scan Completed Charito Love Phase 3 2016-05-16 The primary goal of the analysis is to estimate the diagnostic accuracy of Gallium 68 (68Ga) -DOTATOC PET/CT for detecting neuroendocrine tumors (NETs) compared to conventional imaging techniques such as Magnetic Resonance Imaging (MRI) and Computerized Tomography (CT). Participants with histologically and/or clinically confirmed and/or suspected NET will be enrolled.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for GALLIUM DOTATOC GA 68

Condition Name

Condition Name for GALLIUM DOTATOC GA 68
Intervention Trials
Neuroendocrine Tumors 4
Neuroblastoma 1
Multiple Endocrine Neoplasia Type 1 1
Metastatic Well Differentiated Neuroendocrine Neoplasm 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for GALLIUM DOTATOC GA 68
Intervention Trials
Neuroendocrine Tumors 5
Carcinoid Tumor 3
Neoplasms 2
Meningioma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for GALLIUM DOTATOC GA 68

Trials by Country

Trials by Country for GALLIUM DOTATOC GA 68
Location Trials
United States 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for GALLIUM DOTATOC GA 68
Location Trials
Iowa 2
Texas 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for GALLIUM DOTATOC GA 68

Clinical Trial Phase

Clinical Trial Phase for GALLIUM DOTATOC GA 68
Clinical Trial Phase Trials
Phase 3 2
N/A 2
Early Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for GALLIUM DOTATOC GA 68
Clinical Trial Phase Trials
Active, not recruiting 2
Completed 1
No longer available 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for GALLIUM DOTATOC GA 68

Sponsor Name

Sponsor Name for GALLIUM DOTATOC GA 68
Sponsor Trials
National Cancer Institute (NCI) 2
University of Iowa 1
National Institutes of Health (NIH) 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for GALLIUM DOTATOC GA 68
Sponsor Trials
Other 6
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
McKinsey
Harvard Business School
Dow
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.